Menu Search
Equities

InnoCare Pharma Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
33C:FRA

InnoCare Pharma Ltd

Actions
  • Price (EUR)1.24
  • Today's Change0.00 / 0.00%
  • Shares traded25.00
  • 1 Year change+81.02%
  • Beta1.3003
Data delayed at least 15 minutes, as of Jan 30 2026 07:21 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

InnoCare Pharma Ltd is a China-based company mainly engaged in the research and development, production and commercialization of biopharmaceuticals. The Company focuses on areas with unmet clinical needs, such as oncology and autoimmune diseases. The Company's primary product pipeline includes Orelabrutinib, Tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-B05, ICP-332, ICP-488, ICP-192, ICP-723, ICP-033 and ICP-189, and others. Its products are mainly used to treat hematological tumors, solid tumors and autoimmune diseases. The Company is also developing products for the treatment of autoimmune diseases caused by abnormal T cell function. The Company conducts its businesses in domestic and overseas markets.

  • Revenue in HKD (TTM)1.49bn
  • Net income in HKD-235.09m
  • Incorporated2015
  • Employees1.18k
  • Location
    InnoCare Pharma LtdBuilding 8, No. 8Life Science Park Road, ZhongguancunLife Science Park, Changping DistrictBeijing 102206ChinaCHN
  • Phone+86 1 066609913
  • Fax+86 1 060702992
  • Websitehttps://www.innocarepharma.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		688428:SHH since
announced		Transaction
value
Guangzhou Innocare Pharma Tech Co LtdAnnounced20 Aug 202520 Aug 2025Announced-24.49%65.07m
Data delayed at least 15 minutes, as of Feb 06 2026.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.